Just thought to briefly put ZLD news over the past 2 years. Most of the price sensitive announcements and their highlights, we are on track with some delays but definitely the future looks promising!
------------------------------------------------------------- 04/09/2018 Zelda Forms New Partnership to Access German Market Ordinary Shares: 755,341,934 Options: 49,000,000 1,500,000 ($0.04 – 6/2/2020) - *4,500,000 ($0.04 – 6/2/2020) - 1,000,000 ($0.125 – 22/8/2021) - *3,000,000 ($0.125 – 22/8/2021) 40,000,000($0.03125 – 17/11/2021) • Provides Zelda with ready access to the rapidly growing German market upon successful completion of clinical trials ------------------------------------------------------------- 26/09/2018 First Patient Dosed in Zelda Insomnia Trial • Preliminary results expected 1H-2019 ------------------------------------------------------------- 10/10/2018 US Autism Observational Study Underway • Preliminary results expected first half of 2019 ------------------------------------------------------------- 06/12/2018 SUD: SUDA Enters Agreement To Develop Cannabinoid Spray *No idea what happened to the money invested here! • Under the terms of the Agreement Zelda will pay SUDA an optionfee of $200,000 consisting of an upfront of $100,000 and a further $100,000 indownstream milestone payments. Zelda will also fund the formulation work. The 24-month option provides ZELDA with an exclusive right to extend the Agreement and toenter into a global development and licensing agreement for the oral spray formulationsdeveloped by SUDA ------------------------------------------------------------- 06/03/2019 Aus Patent For Novel Prognostic Marker for Breast Cancer Ordinary Shares: 755,341,934 Options: 85,700,000 • Patent provides protection until 2038 ------------------------------------------------------------- 12/03/2019 Zelda Partners with Ilera HealthCare Ordinary Shares: 755,341,934 Options: 85,700,000 • Provides Zelda access to established medicinal cannabis markets in US states with >80,000 registered patients. ------------------------------------------------------------- 02/07/2019 Zelda Granted Approval for Opioid Reduction Trial Ordinary Shares: 755,341,934 Options: 85,700,000 • Trial at St Vincent’s Hospital Melbourne to begin immediately with final results by Q4 2019 • Outcomes will feed in to larger Phase II trial ------------------------------------------------------------- 18/07/2019 Zelda Collaborates with Emerald Clinics • Zelda will pay Emerald an initial fee of $40,000 to access existing de-identified data for patients prescribed medicinal cannabis for treatment of pain and/or insomnia, whilesubscription fees for the additional data-modules will be negotiated at a later date. ------------------------------------------------------------- 22/08/2019 Zeldas Autism Observational Study Recruits 100th Participant Ordinary Shares: 757,341,934 Options: 83,700,000 • Currently, there are 103 participants enrolled in the study, with the final target of 150 expected by early 2020. ------------------------------------------------------------- 09/10/2019 Zelda to merge with US-based Ilera Therapeutics Ordinary Shares: 757,341,934 Options: 83,700,000 (a) 113,601,290 fully paid ordinary shares in the Company (Consideration Shares); and (b) 362,620,322 Class A Performance Rights; Performance Rights received bythe Company or its subsidiaries from US-based product sales exceeds US$1,000,000. (c) 362,620,322 Class B Performance Rights, Performance Rights received bythe Company or its subsidiaries from US-based product sales exceeds US$2,500,000 ------------------------------------------------------------- 07/11/2019 Zeldas Phase II Insomnia Clinical Trial Fully Enrolled • Preliminary results expected by February 2020 ------------------------------------------------------------- 21/11/2019 Agreement with Health House to Distribute Zelda Products Ordinary Shares: 758,841,934 Options: 83,596,667 • Plans are underway to launch HOPE® and the Insomnia product in global markets from early 2020 ------------------------------------------------------------- 04/12/2019 Zelira Therapeutics expands HOPE distribution in the U.S.A • Available in Louisiana, a state with approximately 5 million residents, in First Quarter 2020 ------------------------------------------------------------- 05/02/2020 Zelira Successfully Completes Capital Raising of $4.6M • Zelira has successfully completed a placement of 91,770,000 fully-paid ordinary shares at a share price of A$0.05 to Australianand International investors. The Placement will raise A$4,588,500 before costs (“Placement”). ------------------------------------------------------------- 19/02/2020 Zelira Meets Primary Endpoints for Insomnia Trial • Poised to launch world’s first clinically validated medicinal cannabis product for insomnia in 2020 • Expands Zelira’s product portfolio alongside the HOPETM product range ------------------------------------------------------------- 27/02/2020 Phase 1 Opioid Reduction Clinical Trial Fully Enrolled • Dosing to be completed by end of April 2020 • Study report expected by mid 2020 ------------------------------------------------------------- 28/02/2020 Appendix 4D & FY20 Interim Financial Report * Lots of details, if interested here is the link to the report: https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02209076 ------------------------------------------------------------- 07/04/2020 Insomnia Trial Meets Primary and Secondary Endpoints • On-track to launch world’s first clinically validated medicinal cannabis product for insomnia in 2020. ------------------------------------------------------------- 30/04/2020 March 2020 Quarterly Report • Insomnia trial successfully meets clinical endpoints • Opioid sparing trial completes recruitment and dosing • Autism observational study completes recruitment• Collaboration progressing with The Parkinson’s Foundation • Capital Raise & Revenues ------------------------------------------------------------- 26/05/2020 TasAlk to Manufacture Zeliras Insomnia and HOPE products • Australian launch of Insomnia and HOPE™ medicinal cannabis products on-track for Q3 2020, whichwould transform Zelira into a fully commercial, revenue generating company in the US and Australia
I will keep updating this with price sensitive news/milestones!
GLTAH & "ALWAYS" DYOR
ZLD Price at posting:
4.9¢ Sentiment: Buy Disclosure: Held
(20min delay)